about
Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICARecognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cellsTumor-associated MICA is shed by ADAM proteasesDiversification, expression, and gamma delta T cell recognition of evolutionarily distant members of the MIC family of major histocompatibility complex class I-related moleculesModulation of NK cell function by genetically coupled C-type lectin-like receptor/ligand pairs encoded in the human natural killer gene complexBACL is a novel brain-associated, non-NKC-encoded mammalian C-type lectin-like receptor of the CLEC2 familyCytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids.The innate immune response in the central nervous system and its role in glioma immune surveillance.Soluble NKG2D ligands: prevalence, release, and functional impact.NK cells and cancer immunosurveillance.Novel APC-like properties of human NK cells directly regulate T cell activationNatural Killer Group 2D Ligand Depletion Reconstitutes Natural Killer Cell Immunosurveillance of Head and Neck Squamous Cell Carcinoma.Vis-à-vis in the NKC: genetically linked natural killer cell receptor/ligand pairs in the natural killer gene complex (NKC).Activating natural cytotoxicity receptors of natural killer cells in cancer and infection.The Activating C-type Lectin-like Receptor NKp65 Signals through a Hemi-immunoreceptor Tyrosine-based Activation Motif (hemITAM) and Spleen Tyrosine Kinase (Syk).Human hematopoietic CD34+ progenitor cells induce natural killer cell alloresponses via NKG2D activation.Dedicated immunosensing of the mouse intestinal epithelium facilitated by a pair of genetically coupled lectin-like receptors.Altered microRNA expression after infection with human cytomegalovirus leads to TIMP3 downregulation and increased shedding of metalloprotease substrates, including MICA.Genetically coupled receptor-ligand pair NKp80-AICL enables autonomous control of human NK cell responses.Attenuated natural killer (NK) cell activation through C-type lectin-like receptor NKp80 is due to an anomalous hemi-immunoreceptor tyrosine-based activation motif (HemITAM) with impaired Syk kinase recruitment capacity.Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses.The polymorphic HCMV glycoprotein UL20 is targeted for lysosomal degradation by multiple cytoplasmic dileucine motifs.Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction.Cutting edge: NKp80 uses an atypical hemi-ITAM to trigger NK cytotoxicity.Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancerThe BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the alpha2 domain.Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.NKp80 defines and stimulates a reactive subset of CD8 T cells.Inhibition of hepatitis B virus replication by small interference RNA induces expression of MICA in HepG2.2.15 cells.Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma.Induction of MHC class I-related chain B (MICB) by 5-aza-2'-deoxycytidine.TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients.BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.Expression of toll-like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL-8 release and up-regulation of NKG2D-ligands.Activation of V gamma 9V delta 2 T cells by NKG2D.RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid.
P50
Q24291172-11A3182A-C91D-4438-927D-B68A50D0FC17Q24316370-761968B5-FB94-43A4-8388-18D102F5FBB1Q24320055-5C663B65-9B96-4ECF-A0C8-19C59AAB9C6DQ24645409-F69ECC93-A9ED-46A8-8BA5-2E8E70808D01Q27001661-0A33777B-E7D0-49CF-BDB1-5B3C7291F613Q28533797-E0E33791-5A7F-4876-BCF2-5E5E4DF46E08Q30648415-DAFD916D-36C0-435E-9C20-DE7DEE04A68BQ35977074-3D75D62D-369F-42D2-B054-304FF1EE5E48Q37175094-4CED0BEA-2712-44B4-9B29-BEF11B553EC4Q37287176-D0DB591E-6B0B-4566-B1B2-D5BEAC8279B6Q37625916-BF266B96-E92E-4412-A69B-5A56CADACA54Q37743484-5F1E9A83-8BE0-4159-A59B-8F19E536BC92Q37855433-929C67E1-2851-45F7-9B98-513A4D0D6844Q38082002-45767FA9-1426-4B0E-BD3D-076205CBA7A4Q38721535-4C7EC648-2825-49B9-90A6-B9E14C36C14AQ38827009-45B4AB35-97C6-4AA5-96E2-856802E6A8E3Q38979002-DA1C50C3-4295-4DA5-958D-89FB9C6580FCQ38980178-133A59C9-2DDB-4556-ADF8-DF1B0B279B50Q39113103-2A67A45D-ED84-4C29-94AD-E0C469FB0F90Q39162160-10DFF88F-C813-4026-9227-A46AC62E82E9Q39176227-0DEEBAE4-0D76-459E-BF56-323BF6F7171AQ39325682-6506E920-07B8-444D-98E1-2F3082457C97Q39521419-D0BBFB67-CD06-41C6-A544-7B33941765C5Q39537390-9BEBB647-BF83-48E2-AEED-289B52491A33Q39621134-317F2487-BA4D-4149-A50D-8A3D139B47EFQ39676621-BA3454F5-7293-4B41-A2F0-B6D0F739ED55Q39741862-D40B44FE-7218-4346-B440-31DBB59806D3Q39854967-266F432E-F73D-4BA1-B290-51D1D9D34DF3Q39904227-54D77407-8E28-4959-8E14-E5238F190194Q39929094-F2C087F6-33B4-4567-B52F-FB2950B512AEQ39953129-C93F9ED9-42F3-4080-A607-AB5605BB40A7Q39976187-67B52371-2139-4E72-9D4F-6A1700DC2DC4Q39994222-014C63A2-6FB5-414B-B516-0EEFBDF17E41Q40246842-3FFCC0CB-498C-4A13-9B95-801F6A11981FQ40280283-D1D8F4A2-9CCD-46EF-A3D0-BCAADE0BD0E7Q40296130-0CE87007-3DF8-45E4-B44C-E4F3754CE148Q40350212-83170E68-415E-4978-A96E-16A71E2BCBB6Q40388491-6249EDBD-1E05-4062-9DAC-F2BA02B7176FQ40474790-9B7B8669-18AD-47A7-B97B-6B5759E94BACQ40479856-60AAA0FB-FB0C-4557-9AA0-34B9842A5A8A
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Alexander Steinle
@ast
Alexander Steinle
@en
Alexander Steinle
@es
Alexander Steinle
@nl
Alexander Steinle
@sl
type
label
Alexander Steinle
@ast
Alexander Steinle
@en
Alexander Steinle
@es
Alexander Steinle
@nl
Alexander Steinle
@sl
prefLabel
Alexander Steinle
@ast
Alexander Steinle
@en
Alexander Steinle
@es
Alexander Steinle
@nl
Alexander Steinle
@sl
P214
P106
P1153
6603750921
P21
P214
P31
P496
0000-0001-5081-8503
P735
P7859
viaf-171284519